No Data
Noda: Extraordinary Report
Individual stock Global Strategy: Focus on Rakuten HD and Resort Tora, ETC.
On the American stock market on the 16th, the Dow Jones Industrial Average fell by 68.42 dollars to 43,153.13, the Nasdaq Composite Index decreased by 172.94 points to 19,338.29, and the Chicago Nikkei 225 Futures were down by 335 yen compared to the Osaka daytime at 38,335 yen.
Noda To Go Ex-Dividend On November 27th, 2025 With 18 JPY Dividend Per Share
January 17th (Japan Standard Time) - $Noda(7879.JP)$ is trading ex-dividend on November 27th, 2025.Shareholders of record on November 30th, 2025 will receive 18 JPY dividend per share. The ex-
Noda To Go Ex-Dividend On May 29th, 2025 With 18 JPY Dividend Per Share
January 17th (Japan Standard Time) - $Noda(7879.JP)$ is trading ex-dividend on May 29th, 2025.Shareholders of record on May 31st, 2025 will receive 18 JPY dividend per share. The ex-dividend date is
Hogimedia, 3rd quarter operating profit decreased by 2.3% to 3.406 billion yen.
Hogi Medica <3593> announced that for the third quarter of the fiscal year ending March 2025, revenue increased by 0.9% year-on-year to 30 billion 16 million yen, while operating profit decreased by 2.3% to 3.4 billion 6 million yen. The steady revenue trend was supported by an active proposal of products that assist medical safety, enhance customer operational efficiency, and promote work style reform. Cost of sales was impacted by the soaring prices of imported materials due to the depreciation of the yen, the disposal of long-stay items, and the reassessment, which led to inventory valuation losses occurring at 1.7.
Key points of interest for the 16th PTS = Helios, DWTI, Rakuten HD, ETC.
▽ Torasun <6696.T> announced that it has received an order for the development of Set-Top Box (STB) terminals and associated software, with an order amount of 44 million yen. This order will contribute to the performance for the fiscal year ending January 2026, for which plans will be announced in the future. ▽ Helios <4593.T> announced that it has reached a basic agreement for a business partnership with Cell Solutions, a subsidiary of Alfreza <2784.T>, regarding the production of cell culture supernatant. ▽ Raqualia Pharma <4579.T> announced the development of TRPV4 antagonists.